Allergan pays Exicure $25M to discover hair loss drugs by Nick Paul Taylor Thursday, November 14, 2019 Exicure is set to receive $25 million upfront to apply its spherical nucleic acid technology to two collaborative programs.
Exicure plans checkpoint combo after TLR9 drug clears early test by Nick Paul Taylor Thursday, September 20, 2018 The first-in-human clinical trial suggested that AST-008 is safe, tolerable and boosts cytokine levels.
Immune cell compound could treat multiple autoimmune diseases by Amirah Al Idrus Friday, April 20, 2018 Itaconate, a compound produced by inflammatory cells, relieved psoriasis-like symptoms in mice.
Exicure raises $11.2M as psoriasis assets near clinical trials by Nick Paul Taylor Monday, November 6, 2017 Exicure has pulled in more cash, branching out beyond the tech investors that bankrolled its atypical rise to as it moves into the clinic.
Purdue bags rights to Exicure's psoriasis gel by Phil Taylor Tuesday, December 13, 2016 Exicure just signed up its first partnership deal, with Purdue offering up to $790 million for rights to its lead psoriasis drug and other projects.
